PDS Planning Inc Increases Position in Boston Scientific Corporation $BSX

PDS Planning Inc lifted its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 11.5% during the second quarter, Holdings Channel reports. The fund owned 8,931 shares of the medical equipment provider’s stock after purchasing an additional 918 shares during the quarter. PDS Planning Inc’s holdings in Boston Scientific were worth $959,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Vanguard Group Inc. increased its position in shares of Boston Scientific by 1.3% during the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock worth $13,577,311,000 after acquiring an additional 1,697,945 shares during the last quarter. Invesco Ltd. increased its position in shares of Boston Scientific by 5.3% during the first quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider’s stock worth $1,677,124,000 after acquiring an additional 834,274 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Boston Scientific by 10.8% during the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock worth $1,426,779,000 after acquiring an additional 1,383,524 shares during the last quarter. Amundi increased its holdings in Boston Scientific by 2.6% in the first quarter. Amundi now owns 12,308,715 shares of the medical equipment provider’s stock valued at $1,212,408,000 after buying an additional 311,034 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Boston Scientific by 4.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 11,299,942 shares of the medical equipment provider’s stock valued at $1,139,938,000 after buying an additional 460,580 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Performance

Shares of BSX stock opened at $95.41 on Friday. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The business has a 50 day moving average of $101.98 and a two-hundred day moving average of $101.87. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The company has a market cap of $141.38 billion, a P/E ratio of 56.79, a PEG ratio of 2.34 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the previous year, the firm posted $0.62 earnings per share. Boston Scientific’s quarterly revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on BSX shares. Erste Group Bank lowered Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. Jefferies Financial Group reissued a “hold” rating on shares of Boston Scientific in a report on Monday, July 21st. UBS Group boosted their price objective on Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a report on Thursday, July 24th. Leerink Partnrs raised Boston Scientific to a “strong-buy” rating in a report on Monday, June 16th. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $120.71.

Insiders Place Their Bets

In other news, Director Edward J. Ludwig sold 4,000 shares of the business’s stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the transaction, the director directly owned 18,479 shares in the company, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 174,214 shares of company stock valued at $17,972,457. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.